Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ Stem Cell Selection in Non-Malignant Diseases
NCT01966367Phase 2Active, not recruiting
- Start
- Mar 2013
- Primary completion
- Feb 2030
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CD34 Stem Cell Selection Therapy in bone marrow failure syndrome (BMFS), aplastic anemia, severe congenital neutropenia (SCN), Amegakaryocytic Thrombocytopenia (CAMT), Diamond-Blackfan anemia (DBA). Started Mar 2013; status: active, not recruiting.
02
Drugs
CD34 Stem Cell Selection Therapy
03
Conditions
bone marrow failure syndrome (BMFS)aplastic anemiasevere congenital neutropenia (SCN)Amegakaryocytic Thrombocytopenia (CAMT)Diamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT01966367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966367.